Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM), a company that deals with the development of targeted radiotherapies, announced on Friday that it has named Lynn Bodarky as its new chief business officer.

In the new role, Bodarky is to head the firm's business development, licensing, and collaboration activities.

The company said that Bodarky has more than 25 years of proven business development and licensing experience at large global pharmaceutical and innovative biotechnology companies, including Pfizer, Merck, Progenics and HiFiBiO. She has served as senior vice president, global head of Business Development & Operations at HiFiBiO, vice president, Business Development at Geron Corporation. She has worked in senior roles focused on vaccines and corporate affairs at Wyeth and then Pfizer. She has also served as vice president of Marketing at Progenics Pharmaceuticals, Inc. She has also worked at Pharmacia Corporation and Merck & Co.